Physician profile
Nikki Patel
NPI 1801030135
$5,247.80
in general payments reported to CMS, 2019-2025
29 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $152 · 2021: $252 · 2023: $1,376 · 2024: $976 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.72 |
| Education | $178.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $877.03 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $707.01 | 2019-2025 | Fasenra, Tezspire, Daliresp |
| Genzyme Corporation | $680.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $572.54 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $343.72 | 2020-2025 | Cuvitru, Takhzyro |
| Csl Behring | $264.51 | 2019-2025 | Hizentra, Haegarda |
| Amgen INC. | $212.41 | 2020-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.00 | 2024-2025 | Ofev |
| Pharming Healthcare, INC. | $164.30 | 2023-2025 | Ruconest |
| Genentech USA, INC. | $150.38 | 2019-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $122.80 | 2025 | Neffy |
| Lilly USA, LLC | $113.40 | 2021 | |
| Kaleo, INC. | $100.00 | 2023-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $95.62 | 2023-2025 | |
| Octapharma USA, INC. | $73.13 | 2021-2024 | Cutaquig |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $67.69 | 2021-2024 | Orladeyo |
| Horizon Therapeutics Plc | $61.28 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Grifols USA, LLC | $54.82 | 2024 | Xembify |
| Alk-Abello, INC | $53.69 | 2023 | Ragwitek, Odactra, Grastek |
| Pfizer INC. | $50.44 | 2019-2024 | |
| Blueprint Medicines Corporation | $45.89 | 2023 | Ayvakit |
| Optinose US, INC. | $40.27 | 2025 | |
| Genentech, INC. | $39.95 | 2019 | |
| Incyte Corporation | $28.42 | 2025 | Opzelura |
| Organon LLC | $27.56 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.11 | 2025 | Alvesco |
| Phadia US INC. | $17.94 | 2020 | |
| Hikma Pharmaceuticals USA | $17.17 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikki Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.